Migraine in Women — Body Handbook

Healthcare · §642

Migraine in Women

Migraine hits women about three times more often than men, and the reason isn't stress or temperament — it's how the brain responds to swings in estrogen. The single most consequential question for any woman with migraine is whether she has aura, because aura paired with the standard combined birth-control pill multiplies stroke risk on top of an already-elevated baseline. The hormonal story shapes everything that follows: which contraceptive is safe, how pregnancy reshapes attacks, why perimenopause is usually the worst stretch, and which of the new preventive treatments actually work.

Decide · As-needed Evidence Moderate Chapter Healthcare

The single biggest leverage point is the aura question — visual flicker, blind spots, or word-finding trouble before the headache changes the contraceptive math entirely, and most women carrying that risk have never been asked. Past that, the modern preventive toolkit moves a typical eight-to-ten-attack month down to three-to-five for roughly half the women who try it. The decisions are clinician-led but reader-driven: knowing what to ask for shortens the path to a livable headache load by years.

The clearest single fact about migraine in women is that it isn't a stress response or a tension headache wearing a different name — it's a neurological disease whose trigger pattern follows the cycle. Rising estrogen quiets the brain's pain pathways; falling estrogen sets attacks off. Low estrogen by itself doesn't trigger; the drop does. That's why a nine-year-old who hasn't started cycling doesn't get cyclical migraine, and a sixty-five-year-old whose estrogen is uniformly low usually feels better than she did at forty-five.

The downstream machinery is shared with male migraine — pain nerves around the lining of the brain release a chemical messenger called CGRP (calcitonin gene-related peptide) that drives the throbbing, light-sensitive, nausea-heavy headache phase. The hormonal layer on top is what makes women's migraine a different clinical problem than men's. Most of what's new in prevention since 2018 blocks the CGRP pathway directly.

How big the problem actually is

One in three women will have migraine in her lifetime; about one in six has had an attack in the last year. Among men the numbers are roughly one in seven and one in eighteen (Lipton et al. 2007). Prevalence peaks in the thirties — the decade of career consolidation and small children — and starts to fall again only after menopause. Globally, migraine is the leading cause of years of life lived with disability in women aged fifteen to forty-nine (GBD 2016 Headache Collaborators). That ranking is in front of every other condition women that age live with: depression, anxiety, low back pain, the lot.

Roughly a quarter to a third of women with migraine have aura — visual scintillations, blind spots, sensory tingling, or word-finding trouble in the half-hour before the headache hits. Aura is the subset that carries the elevated stroke baseline; meta-analytic data across roughly six-hundred-thousand women put the relative ischemic-stroke risk in migraine with aura at about two times the baseline (Schurks et al. 2009). Identifying aura is the single most important clinical question for a woman with migraine, because the answer changes what's safe and what isn't.

Aura plus the combined pill: don't

If you have visual aura — even rarely, even mild — the standard combined birth-control pill, patch, and ring are off-limits. The aura subgroup carries roughly twice the baseline ischemic-stroke risk on its own; estrogen-containing contraception roughly doubles stroke risk again; the combination puts a young woman's stroke risk at an estimated six to nine times the population baseline. Smoking on top of either compounds further. Every major guidelines body — WHO, the U.S. CDC, the European Headache Federation, the American Headache Society — classifies the combined pill as an absolute contraindication in migraine with aura, the highest category their frameworks define (WHO Medical Eligibility Criteria 2015; U.S. MEC 2016; Sacco et al. 2017).

What's left? Most of contraception, in fact. Progestin-only pills, the etonogestrel implant (the small rod placed under the skin of the upper arm), the hormonal IUD, and the copper IUD are all safe regardless of aura status — they don't carry the estrogen-related stroke signal. If you've spent years being told you can't use hormonal contraception because of your migraines, the conversation that's owed you is about those progestin-only methods.

Migraine without aura is a different calculation: the combined pill is generally fine under thirty-five with no smoking and normal blood pressure, and many women with migraine without aura tolerate it well. Above thirty-five, with smoking, or with hypertension, the math tightens. Ask a clinician who actually opens the eligibility criteria.

Pregnancy carries its own contraindication list. Valproate causes neural-tube defects and lower IQ in exposed pregnancies and is off the table. Topiramate raises the risk of cleft palate at first-trimester exposure and is usually stopped before conception. NSAIDs are avoided in the third trimester. The CGRP-blocking injections and pills don't have enough pregnancy safety data yet and are typically stopped at least five months before trying to conceive. What's left for pregnancy: acetaminophen, magnesium, biobehavioural work, and — when prevention is genuinely needed — propranolol or metoprolol.

What untreated migraine costs you, decade by decade

The week-to-week story is the one you already know — two or three days a month vanish, you push through the rest at maybe seventy percent, the people who live with you learn to read the storm coming. The decade story is the one most women don't see in advance.

In your thirties, the cost shows up as cancelled plans and a quiet recalibration of what you can take on at work. A promotion you don't push for because you can't guarantee the Tuesdays. Children's birthday parties your partner runs alone. You learn the exact smell of your apartment in a dark room because that's where you spend two days a month.

In your forties, perimenopause arrives, and the AMPP cohort data show that high-frequency headache — ten or more days a month — becomes about half again as common in perimenopausal women with migraine as in premenopausal ones, with the worst version reserved for women whose menopause is surgical or chemotherapy-induced (Martin et al. 2016). The attacks that used to space themselves out start crowding. Hot flashes wreck your sleep; the disrupted sleep feeds the migraine; mood erodes. Roughly a quarter of women with migraine also live with depression or anxiety by this point, and the two feed each other in ways that make either one harder to treat alone. The colleagues who quietly worked around you in your thirties start to look like they're being patient.

Into your fifties and beyond, natural menopause does help most women — about two-thirds see attacks ease once cycles stop. But if you reached the back end of perimenopause without ever getting a real diagnosis or modern prevention, you spent the highest-earning, highest-responsibility decade of your life at about three-quarters strength. That's the actual stake.

What good migraine care looks like in 2026

The first move is a three-month headache diary — date, intensity, duration, period, medications used, anything that looked like aura. Paper notebook, phone app, doesn't matter. It tells the clinician what you actually have, whether attacks are menstrually patterned, and whether you've slid into medication-overuse headache (using acute medication ten or more days a month, which converts episodic migraine into chronic and blocks both acute and preventive relief until you back off).

For the attack itself, the standard acute therapy is a triptan — sumatriptan, rizatriptan, eletriptan — taken at the first sign, not when the headache is already full-blown. Adding five hundred milligrams of naproxen on top boosts response when the triptan alone isn't enough. If triptans are off the table because of cardiovascular concerns, the newer gepants (rimegepant, ubrogepant) work without the blood-vessel constriction.

Prevention enters the picture once you're losing four or more days a month to attacks, or once acute therapy isn't holding. The 2021 American Headache Society consensus statement now allows the new CGRP-pathway drugs as first-line preventives without requiring you to fail topiramate or propranolol first (AHS 2021). The menu: monthly under-the-skin injections of erenumab, fremanezumab, or galcanezumab; a quarterly IV of eptinezumab; or oral options — atogepant daily, rimegepant every other day.

If you've crossed into chronic migraine — fifteen or more headache days a month — onabotulinumtoxinA (the Botox protocol, in a specific scalp, forehead, neck, and shoulder pattern, every twelve weeks) is the long-established option (PREEMPT trials, Dodick et al. 2010). It's a fifteen-minute office procedure.

The lifestyle layer matters and is unglamorous: consistent sleep timing (irregular sleep and oversleeping both trigger attacks), aerobic exercise three times a week (effect size on par with topiramate in small trials), and trigger work through the diary. Magnesium four hundred to six hundred milligrams a day and riboflavin (B₂) four hundred milligrams a day have small but real preventive effects and a clean safety profile — reasonable to layer on top, especially in pregnancy when the prescription options narrow. CoQ10 belongs in the same low-risk tier, with modest but real evidence behind it.

Life stage changes the playbook

The hormonal trigger pattern means the same diagnosis carries different decisions at twenty-five, forty-five, and sixty-five. Three windows are worth naming separately.

Trying to get pregnant, or pregnant

The good news first: roughly four out of five women with migraine see attacks ease through pregnancy, most by the end of the first trimester, most fully by the second (Sances et al. 2003). The exception is women with aura — they remit less reliably, and new-onset aura during pregnancy is well-described. The bad news is the postpartum estrogen crash brings attacks back within the first month for most women, and the preventive toolkit shrinks during pregnancy: stop CGRP-blocking drugs five months before trying to conceive, stop topiramate and valproate before conception, NSAIDs out of the third trimester. What stays in: acetaminophen, magnesium, biobehavioural work, propranolol or metoprolol if real prevention is needed.

Perimenopause — usually the worst stretch

Cycle-to-cycle estrogen swings get wilder before they get smaller; attacks intensify accordingly. If you're considering hormone replacement therapy for hot flashes or sleep, the migraine layer matters — transdermal estradiol patches give steadier blood levels than oral pills, are less likely to provoke migraine, and are the preferred preparation when HRT is otherwise indicated. Surgical or chemotherapy-induced menopause tends to worsen migraine sharply; planning ahead with a headache specialist before bilateral oophorectomy is worth the extra appointment.

After menopause

About two-thirds of women see attacks ease once cycles stop entirely; a third don't, and the playbook stays the same as before. New-onset headache after sixty is a different question, though — it warrants imaging and inflammatory markers (to rule out giant cell arteritis) before being assumed to be migraine.

What most women get told that's wrong

Four things keep coming up.

"It's just a bad headache." It's a neurological disease with prodromal, aura, headache, and postdromal phases driven by specific brain circuits. The global disability ranking — number one for women aged fifteen to forty-nine — is not a metaphor (GBD 2016 Headache Collaborators).

"The pill triggers my migraines, so hormonal contraception isn't an option for me." The combined pill, which contains estrogen, triggers attacks during the placebo week. The progestin-only options — the mini-pill, the implant, the hormonal IUD — usually don't, because they keep hormones steady. They're explicitly recommended in the same guidelines that ban the combined pill in aura.

"My migraines will stop at menopause, so I just have to wait." Perimenopause typically gets worse before menopause gets better. The wait is years, often the highest-disability years of life.

"Nothing really works for migraine." True a decade ago for many women; not true now. The CGRP-pathway drugs since 2018 are the largest jump in migraine therapeutics in twenty-five years (AHS 2021). The challenge is access, not efficacy.

Where care actually goes wrong

Four patterns dominate the gap between what works and what most women receive.

Never reaching a headache specialist. Most women see only their GP or gynecologist, and most of the modern preventive toolkit lives outside the standard primary-care playbook. The fix is asking explicitly for a referral; the United Council for Neurologic Subspecialties certifies headache specialists and maintains a directory.

Missed aura. Visual changes in the half-hour before a headache aren't always volunteered — many women have lived with them long enough to consider them part of the headache. They aren't. If a clinician hasn't asked specifically about visual scintillations, blind spots, sensory tingling, or word-finding trouble before the pain, the question hasn't been asked yet.

Medication-overuse headache. Taking acute pain medication ten or more days a month — including over-the-counter combinations with caffeine — converts episodic migraine into a chronic daily headache that doesn't respond to either acute or preventive treatment until the offending agent is withdrawn for a couple of months. Opioid- and barbiturate-containing combinations (still common in U.S. primary care) accelerate the transition.

Insurance step-therapy. CGRP-pathway monthly injections list at six hundred to seven hundred dollars a month retail in the U.S.; with insurance and manufacturer copay cards most insured patients end up paying zero to thirty dollars a month, but plans typically require documented failure of two older preventives first. That's a delay barrier rather than a clinical one — the American Headache Society consensus explicitly pushes against it (AHS 2021) — but it's the largest practical obstacle to modern care.

What changes when you actually treat it

The legacy preventives take eight to twelve weeks to titrate to effect; the CGRP-pathway injections show benefit within four to twelve weeks, sometimes the first month. Trials measure success as monthly migraine days dropping — a typical responder moves from eight to ten attack days down to three to five (Goadsby et al. 2017; Stauffer et al. 2018). The felt experience of that arithmetic is the bigger story.

Inside three months, the "I can't commit to that Tuesday" hedge starts coming out of the calendar. Inside six, the friends who'd learned the bracing pattern of your cancellations start to comment on having you back; the dark room hasn't been needed in weeks. Inside a year, the way you'd organized work and parenting around an attack ceiling you'd assumed was permanent quietly unwinds. About four or five women in ten respond strongly to the first preventive they try; the rest cycle through a second or third agent and most land somewhere good. The non-responders are the open clinical problem, but the responder share is large enough that most women who go through the full modern protocol come out somewhere different from where they started.

For women with aura who switch off the combined pill onto a progestin-only or copper-IUD method, the change isn't felt in the body — the stroke-risk multiplier just stops compounding silently in the background, year after year. For women navigating perimenopause with transdermal estradiol patches instead of an oral combined HRT, the attacks track downward across the years they used to dominate, rather than upward.

Adjacent things worth knowing about: tension-type headache (different mechanism, lower disability, different management); medication-overuse headache as a topic on its own if you've already crossed into it; cluster headache and the other trigeminal autonomic cephalalgias (mostly male-predominant, very different toolkit); idiopathic intracranial hypertension (also female-predominant but driven by weight and pressure, not hormones, and its visual changes can mimic aura). And if your attacks ever change in character — sudden onset, new neurological signs that don't resolve in an hour, the worst headache of your life — that's an emergency-room question, not a migraine question.

Related in the handbook

Helps

— The modern preventives that finally work for many women are the CGRP drugs — the toolkit this page points you toward.
— CoQ10 is one of the low-risk supplements with real evidence for migraine prevention.
— Daily magnesium is one of the low-cost preventives worth trying for migraine, especially around the cycle.

— Aura isn't just a headache feature; it nudges up stroke and heart risk, which is why it changes the contraception you should be on.
— Migraine with aura plus the combined pill multiplies stroke risk — the single most important question to settle here.
— The hormonal turbulence of perimenopause is a major driver of changing migraine.
— Aura status shapes which menopausal hormone options are safe, the same way it governs contraception.
— If attacks cluster around your period, a cycle log proves the hormonal pattern and points to when prevention should kick in.
— Migraine and Raynaud's tend to travel together, both involving blood vessels that overreact.
— Migraine and TMJ jaw pain often travel together on one overloaded nerve circuit; calming one can ease the other.

Substance and claimed effects

Migraine is a primary neurological disorder of episodic recurrent headache with accompanying sensitivity (light, sound, smell, movement), nausea, and, in ~25-30% of attacks, a preceding focal neurological aura. After puberty it is markedly female-predominant: 1-year prevalence in U.S. women ~17-18% versus ~6% in men, lifetime prevalence ~33% women vs ~13% men, with a 3:1 ratio that opens at menarche, peaks in the 30s-40s, and partially closes after menopause Lipton et al. 2007. The Global Burden of Disease study ranks migraine as the leading cause of years lived with disability in women aged 15-49 worldwide GBD 2016 Headache Collaborators.

This entry covers female-predominant migraine and the consequences that follow from its hormonal patterning: menstrual triggering and the estrogen-withdrawal mechanism; the course of migraine in pregnancy and the postpartum; the contraceptive-choice problem driven by elevated ischemic stroke risk in migraine with aura; the perimenopausal worsening and the relative protection of late post-menopause; and modern preventive therapy options including CGRP-pathway monoclonal antibodies, gepants, onabotulinumtoxinA, and the legacy preventives still used in pregnancy. Out of scope: trigeminal autonomic cephalalgias (cluster), tension-type headache, secondary headaches, and pediatric migraine before menarche.

Evidence by addressing question

Mechanism

Migraine pathophysiology centres on the trigeminovascular system: activation of trigeminal sensory afferents around dural blood vessels releases calcitonin gene-related peptide (CGRP) and other vasoactive neuropeptides, driving neurogenic inflammation, peripheral and central sensitization, and the throbbing, light/sound-sensitive headache phase. Cortical spreading depression — a slow wave of neuronal depolarization followed by suppression sweeping across cortex — underlies aura and probably activates the trigeminal afferents that follow.

The female-specific overlay is estrogen sensitivity of this circuit. Estradiol modulates serotonergic tone, trigeminal nociception, magnesium homeostasis, and CGRP release; trigeminal neurons express estrogen receptors. The clinical hallmark is that falling estrogen, not low estrogen per se, precipitates attacks. Somerville's 1972 experiments established that intramuscular estradiol delayed perimenstrual attacks until the exogenous estradiol level itself fell, while progesterone did not — fixing estrogen-withdrawal as the proximate trigger Somerville 1972. A diary-based cohort confirmed that incidence of migraine without aura rises sharply in the two days before menses and the first three days of bleeding — the days of steepest late-luteal estradiol decline MacGregor et al. 2006. Stable high estrogen (late pregnancy) tends to suppress attacks; oscillating estrogen (perimenopause, the placebo week of cyclic combined oral contraceptives) tends to worsen them Brandes 2006.

Migraine with aura adds a vascular wrinkle: aura is associated with endothelial dysfunction, increased platelet aggregability, and a roughly doubled background risk of ischemic stroke. The mechanism is thought to combine cortical spreading depression-induced vascular changes with shared genetic substrate; the practical consequence is that any further prothrombotic exposure (exogenous estrogen, smoking, uncontrolled hypertension) multiplies on top of an already-elevated baseline Schurks et al. 2009.

Evidence

Female predominance and disability burden. The American Migraine Prevalence and Prevention (AMPP) study, a population sample of ~162,000 U.S. households, established the modern numbers: 1-year migraine prevalence 17.1% in women vs 5.6% in men, with peak prevalence ~24% in women aged 30-39 and substantial functional disability Lipton et al. 2007. GBD 2016 confirmed migraine as the leading specific cause of years-lived-with-disability in women of reproductive age globally GBD 2016 Headache Collaborators.

Menstrual association. Roughly 50-60% of women with migraine report a menstrual association on diary review; perimenstrual attacks (defined as attacks occurring days -2 to +3 of menses) are typically longer, more severe, less responsive to acute treatment, and more likely to recur within 24 hours of initial relief than non-menstrual attacks MacGregor 2015. Pure menstrual migraine (attacks only at menses) is uncommon (~7-10%); menstrually-related migraine (attacks at menses plus attacks at other times) is the more common pattern.

Pregnancy course. Sances and colleagues followed 81 pregnancies in women with pre-existing migraine and found ~47% reported complete remission by the end of trimester one, ~83% by end of trimester two, ~87% by end of trimester three; migraine with aura improved less reliably than migraine without aura, and de-novo aura onset during pregnancy is well documented Sances et al. 2003. The postpartum drop in estrogen drives a recurrence in the first month for most women.

Stroke risk and contraception. Schurks' 2009 meta-analysis (25 studies, ~600,000 women) found migraine with aura roughly doubled ischemic stroke risk (relative risk ~2.16, 95% CI 1.5-3.0); migraine without aura did not significantly elevate the risk Schurks et al. 2009. Combined hormonal contraceptives (containing ethinyl estradiol) independently raise ischemic stroke risk roughly two- to fourfold; the combination with migraine with aura produces an estimated 6-9 fold elevation, with smoking pushing it higher still. The European Headache Federation / European Society of Contraception consensus and the WHO/U.S. Medical Eligibility Criteria for Contraceptive Use therefore classify combined hormonal contraceptives (the pill, patch, ring) as category 4 — absolute contraindication — in women with migraine with aura at any age Sacco et al. 2017 WHO MEC 2015 U.S. MEC 2016. Migraine without aura is category 2 (benefits outweigh risks) in women under 35 and category 3-4 once age, smoking, or hypertension layer on.

Perimenopause. Martin and colleagues used AMPP data on ~3,664 women with migraine to show high-frequency headache (≥10 days/month) was significantly more common in perimenopausal women than in premenopausal women (12.2% vs 8.0%; OR 1.42 after adjustment) and even higher in menopause itself, particularly when menopause was iatrogenic — surgical or pharmacological — rather than natural Martin et al. 2016. Natural post-menopause is on average kinder than perimenopause; about two-thirds of women see improvement once cycles cease.

CGRP-targeted prevention. Four anti-CGRP monoclonal antibodies have FDA approval (erenumab 2018, fremanezumab 2018, galcanezumab 2018, eptinezumab 2020). The phase-3 STRIVE trial of erenumab in episodic migraine (n=955, 6 months) showed mean monthly migraine days fell 3.2 (70 mg) and 3.7 (140 mg) days vs 1.8 placebo, with ≥50% responder rates of 43% and 50% vs 27% placebo Goadsby et al. 2017. Fremanezumab in chronic migraine reduced headache days by 4.3 (monthly dosing) vs 2.5 placebo over 12 weeks, with serious adverse events comparable to placebo Silberstein et al. 2017. Galcanezumab EVOLVE-1 in episodic migraine reduced monthly migraine headache days by 4.7 days (120 mg) vs 2.8 placebo Stauffer et al. 2018. The oral CGRP-receptor antagonists ("gepants") — atogepant in the ADVANCE phase-3 trial (n=873) reduced monthly migraine days by 3.7-4.2 vs 2.5 placebo Ailani et al. 2021, and rimegepant 75 mg every-other-day reduced monthly migraine days by 4.3 vs 3.5 placebo Croop et al. 2021 — give a pill-based alternative with similar effect sizes, and rimegepant doubles as an acute treatment.

OnabotulinumtoxinA for chronic migraine. The pooled PREEMPT analysis (n=1,384) established onabotulinumtoxinA 155-195 units every 12 weeks as effective preventive therapy specifically in chronic migraine (≥15 headache days/month); headache day reduction of 8.4 vs 6.6 placebo at 24 weeks with sustained benefit through 56 weeks Dodick et al. 2010. The American Headache Society 2021 consensus statement endorses CGRP-targeted therapies and onabotulinumtoxinA as first-line options when patients meet appropriate criteria, removing the long-standing requirement to fail two or more traditional preventives Ailani et al. AHS 2021.

Protocol

Diagnosis follows ICHD-3 criteria — at least five lifetime attacks, headache lasting 4-72 hours, at least two of {unilateral, pulsating, moderate-severe, aggravated by routine activity}, plus at least one of {nausea/vomiting or photophobia+phonophobia}. The diary is the diagnostic instrument that matters: a 3-month headache diary recording date, intensity, duration, menstruation, medications and triggers tells the clinician whether attacks are menstrually related, whether medication-overuse headache has emerged (regular use of acute medications ≥10-15 days/month), and whether prevention is indicated.

Acute therapy: a triptan (sumatriptan, rizatriptan, eletriptan) is first-line for moderate-severe attacks in women without cardiovascular contraindications; combined with an NSAID (e.g. naproxen 500 mg) improves response. Gepants (rimegepant, ubrogepant, zavegepant nasal) avoid the vasoconstriction of triptans and are usable in women with cardiovascular contraindications. Cap acute use at ≤10 days/month for triptans/opioids/combinations and ≤15 days/month for simple analgesics to avoid medication-overuse headache.

Preventive therapy is indicated when monthly migraine days ≥4 with disability, ≥8 regardless of disability, or where acute therapy is contraindicated or failing. First-line legacy preventives: propranolol (or metoprolol) 80-240 mg/day; topiramate 50-100 mg/day; amitriptyline 25-75 mg at night; candesartan 16 mg/day. Modern first-line where access permits: CGRP monoclonals (erenumab 70-140 mg SC monthly; fremanezumab 225 mg monthly or 675 mg quarterly; galcanezumab 240 mg loading then 120 mg monthly; eptinezumab 100-300 mg IV quarterly) or oral gepants (atogepant 60 mg daily, rimegepant 75 mg every other day). OnabotulinumtoxinA 155-195 units across 31-39 sites every 12 weeks is the standard for chronic migraine (≥15 headache days/month).

Menstrual-migraine specific protocols: short-term ("mini") prevention with a long-acting triptan (frovatriptan 2.5 mg twice daily or naratriptan 1 mg twice daily) from two days before expected menses through day 3-5 of bleeding; or estrogen-stabilization strategies — continuous (skip-the-placebo) combined oral contraceptive cycling, or an extended-cycle pill — but only in women without aura, and after weighing other contraceptive risks.

Contraindications

Combined hormonal contraception (ethinyl-estradiol-containing pill, patch, or ring) is contraindicated in any woman with migraine with aura, regardless of age, regardless of aura frequency, regardless of smoking status — category 4 in WHO MEC and U.S. MEC WHO MEC 2015 U.S. MEC 2016. Progestin-only methods (progestin-only pill, etonogestrel implant, levonorgestrel IUD, depot medroxyprogesterone, copper IUD) are category 1-2 — safe — and are the standard recommendation when hormonal contraception is wanted alongside migraine with aura Sacco et al. 2017.

Pregnancy contraindications: valproate is teratogenic (neural tube defects, neurodevelopmental impairment) — absolutely contraindicated in pregnancy and discouraged in women of reproductive potential unless robust contraception is in place. Topiramate causes cleft palate at first-trimester exposure and is best stopped before conception. NSAIDs are avoided in the third trimester (premature closure of ductus arteriosus). CGRP monoclonal antibodies and gepants have insufficient pregnancy data; pharmacokinetics (long-lived IgG-class antibodies cross placenta) raise concern and current guidance is to stop CGRP mAbs at least 5 months before planned conception. Triptans: sumatriptan registry data are reassuring but not definitive; use cautiously after first-trimester. Acetaminophen, metoclopramide, and judicious use of magnesium and beta-blockers (excluding atenolol) cover most of the pregnancy toolkit.

Hormone replacement therapy in perimenopause: transdermal estradiol with cyclic or continuous progestin is preferred — it produces less serum-level oscillation than oral preparations and is less likely to provoke migraine; oral combined HRT can worsen migraine. HRT does not appear to substantially alter ischemic stroke risk in non-smokers under 60, but the precaution about migraine-with-aura plus exogenous estrogen retains qualitative force at lower doses; the call should be individualized with a clinician familiar with both menopause and headache.

Misconceptions

"It's just a headache." Migraine is a neurological disease, not a tension or stress symptom; the prodromal, aura, headache, and postdromal phases reflect distinct brain physiology. The disability burden is real: GBD lists it as the top cause of years lived with disability in women of reproductive age GBD 2016 Headache Collaborators.

"My pill gives me migraines, so hormonal contraception is off the table." Combined oral contraceptives, which contain estrogen, drive a withdrawal trigger during the placebo week and can worsen attacks. Progestin-only methods (especially the levonorgestrel IUD and etonogestrel implant) generally do not — they avoid the estrogen swing and are explicitly recommended in WHO/U.S. MEC even in migraine with aura WHO MEC 2015 U.S. MEC 2016.

"My migraines will stop at menopause." Perimenopause typically worsens migraine before improvement arrives; natural menopause does help most women but not all, and surgical menopause tends to worsen migraine sharply Martin et al. 2016.

"There's nothing new for migraine prevention." False since 2018. The four anti-CGRP monoclonals and two oral gepants are mechanistically novel, head-to-head competitive with topiramate/propranolol on efficacy, and substantially better tolerated AHS 2021.

"Aura means stroke is happening." Aura is a transient cortical phenomenon — usually visual scintillations, sometimes sensory or speech changes — that resolves within an hour. It is associated with elevated baseline stroke risk but is not itself a stroke. Sudden, severe, atypical, or persistent symptoms warrant emergency evaluation; classical aura that follows the woman's usual pattern does not.

Audience

The entry is female-scoped end to end. Within that, three life-stage cohorts have distinct guidance:

Reproductive-age women (18-39). The contraceptive-choice problem dominates. Aura screening at every visit; combined hormonal contraception off the table if aura; lifestyle and trigger work plus modern preventives where indicated.
40-59 perimenopausal women. Often the worst period of life for migraine — escalating frequency, treatment changes needed. HRT decisions are entangled with migraine course; transdermal estradiol is the preferred preparation when HRT is otherwise indicated.
60+ women. Post-menopausal prevalence drops substantially; new-onset headache at this age is more concerning for secondary causes (giant cell arteritis, intracranial pathology) and warrants imaging plus inflammatory markers before being attributed to migraine.

Pregnancy and lactation are a separate axis cutting across the reproductive-age band — the preventive toolkit narrows sharply (propranolol and metoprolol remain; valproate and topiramate are out; CGRP-targeting therapy is not recommended; magnesium and biobehavioural work move to first line).

Alternatives

Non-pharmacological options with the strongest evidence: aerobic exercise (40 minutes 3x/week reduces frequency on par with topiramate in small trials), CBT/biofeedback for chronic and stress-loaded patterns, regular sleep (consistent timing matters more than total duration), and trigger identification through diary work. Riboflavin 400 mg/day and magnesium citrate 400-600 mg/day have small but real preventive effects with cheap, safe profiles. Coenzyme Q10 300 mg/day shows weaker but suggestive evidence. These are reasonable first additions before, or alongside, prescription prevention — especially during pregnancy and lactation.

Neuromodulation devices (single-pulse transcranial magnetic stimulation, transcutaneous supraorbital nerve stimulation, remote electrical neuromodulation) have FDA clearance with modest effect sizes and no systemic safety concerns — useful when pharmacological options are exhausted or contraindicated.

Failure-modes

The dominant failure mode is undertreatment via primary care alone. Most women never see a neurologist or headache specialist; available data suggest only a minority of those meeting criteria for preventive therapy are offered one. Aura is routinely missed in history-taking — visual disturbance that lasts 5-30 minutes preceding headache is the classical pattern but many women report it only when asked specifically — and missed aura means missed contraindication.

Medication-overuse headache (MOH) is the second major failure mode: regular use of acute medications (triptans, opioids, combination analgesics ≥10 days/month, simple analgesics ≥15 days/month) converts episodic migraine into chronic daily headache that does not respond well to either acute or preventive treatment until the offending agent is withdrawn. Opioid- and barbiturate-containing acute treatments (still common in U.S. primary care) accelerate this transition.

CGRP-mAb access is gated by insurance prior authorization in most U.S. plans, typically requiring documented failure of two legacy preventives — this is a delay barrier rather than a clinical one, but it is the largest practical obstacle to modern care.

Practicalities

Triptans are generic and cheap. CGRP monoclonals retail $600-700 per monthly injection in the U.S.; manufacturer copay cards and patient-assistance programs commonly bring out-of-pocket cost to $0-30/month for insured patients meeting criteria. Atogepant and rimegepant retail similarly. OnabotulinumtoxinA for chronic migraine is delivered in a 15-minute office procedure every 12 weeks; insurance approval requires documented ≥15 headache days/month for ≥3 months. A genuine headache specialist is the practical bottleneck — they are concentrated in academic centres and major cities; the United Council for Neurologic Subspecialties maintains a directory.

Stakes

Untreated or undertreated migraine in women is not benign waiting. The disability burden compounds: missed workdays, social withdrawal during attacks, partial functioning between attacks, anxiety about the next attack, depression comorbid in ~25%, and downstream effects on career trajectory, parenting, and partnership. Perimenopause, the period when many women are also at career peak and managing teenage children or aging parents, is often the worst period — high-frequency headache 50% more common than in premenopause Martin et al. 2016. The pattern is reversible at most ages with modern preventive therapy, but only if the diagnosis is identified, the patient sees the right clinician, and access barriers are navigated.

Payoff

Effective preventive treatment moves a typical 8-10 day/month migraineur to 3-5 days/month, often within 2-3 months for the legacy preventives and within 4-12 weeks for CGRP-targeted therapy. ≥50% responder rates in modern trials are 40-50% in episodic and 30-40% in chronic migraine Goadsby et al. 2017 Silberstein et al. 2017; super-responders see ≥75% reduction. Switching off combined oral contraception in a woman with aura removes a multiplicative stroke risk without sacrificing contraception (progestin-only methods are equally effective). Transdermal estradiol in perimenopause stabilizes the hormonal trigger while preserving HRT benefits. The lived consequence is recovery of predictable weeks — being able to commit to plans, to work, to parenting without the attack lottery in the background.

Out-of-scope

Related neurological conditions: tension-type headache (the highest-prevalence headache type, lower disability, different management); cluster headache and other trigeminal autonomic cephalalgias (male-predominant, distinct phenotype, different acute and preventive toolkit); medication-overuse headache as a primary topic; idiopathic intracranial hypertension (female-predominant but obesity-driven, not hormonal); pediatric migraine before menarche; hemiplegic migraine and other rare aura subtypes.

Credibility range

Optimist case. The hormonal-trigger story is among the cleanest in headache medicine: estrogen-withdrawal is mechanistically established Somerville 1972, the menstrual-incidence pattern is replicated in modern diary cohorts MacGregor et al. 2006, and stratifying contraception by aura status is supported by large meta-analytic stroke-risk estimates Schurks et al. 2009 codified in WHO/U.S. eligibility criteria WHO MEC 2015 U.S. MEC 2016. CGRP-targeted preventives are a genuine therapeutic advance — multiple phase-3 RCTs, FDA-approved, AHS-endorsed as first-line, mechanistically novel, well-tolerated AHS 2021. A clinician who diagnoses correctly, screens for aura, picks the contraceptive method accordingly, deploys lifestyle plus modern prevention, and treats acutely with adequate triptan/gepant dosing can reliably move the disability needle for most women with migraine.

Skeptic case. Population stroke risk in young women is low in absolute terms — relative risks of 2-9 sit on top of small base rates, and the absolute event count attributable to combined hormonal contraceptive use in migraine with aura, while non-zero, is debated. CGRP-mAb trial effect sizes (1-2 fewer migraine days vs placebo) are modest in absolute terms; placebo response rates are substantial; long-term real-world durability and rare adverse signal (constipation, possible hypertension with erenumab, post-marketing reports of cardiovascular events) are still being characterized. Industry funding pervades the CGRP literature. The perimenopausal pattern, while replicated, is confounded by sleep disruption, mood symptoms, and broader vasomotor instability — the "estrogen oscillation" story may share weight with general perimenopausal dysregulation. Triptan registry data in pregnancy are reassuring but not definitive; conservative practice still moves to acetaminophen first.

Author's call. The aura-plus-estrogen contraindication is the highest-confidence single clinical call in this entry — settled across multiple consensus bodies and codified in eligibility criteria. The hormonal mechanism is settled. CGRP-targeted prevention is a genuine, well-replicated advance and warrants first-line consideration in 2026; absolute effect sizes look smaller than they feel because trial endpoints (mean monthly migraine days) flatten the responder/non-responder split — for the ~45% who respond it is transformative, for the ~55% who don't another agent is tried. Perimenopausal worsening is real but interventions retain efficacy. The entry lands optimistic on management, conservative on hormonal exposure, and disability-aware on stakes.

Stakeholder and incentive map

Pharmaceutical industry. CGRP mAbs and gepants are revenue centres for Amgen/Novartis (erenumab), Teva (fremanezumab), Eli Lilly (galcanezumab), Lundbeck (eptinezumab), AbbVie (atogepant, ubrogepant, onabotulinumtoxinA), Pfizer/Biohaven (rimegepant). Industry-funded trials dominate the modern preventive literature; the AHS consensus discloses industry ties.
Headache specialists and AHS. Professional incentive aligned with broader access to preventive therapy and earlier specialist referral; the 2021 consensus actively pushes against insurance step-therapy requirements.
Insurance payers. Counter-incentive to slow CGRP-mAb adoption via prior authorization; reduces near-term cost but contributes to the under-treatment failure mode.
Reproductive endocrinology and obstetrics-gynecology. Sometimes underweights aura screening in contraceptive counselling; the WHO/U.S. MEC are the relevant guidelines and not all prescribers consult them at every visit.
Patient advocacy. Miles for Migraine, the National Headache Foundation, the American Migraine Foundation push diagnosis and access; the Migraine Research Foundation funds early-career investigators. The community signal is large and consistent — well-curated patient-reported diaries are part of why CGRP-pathway evidence converged on real-world benefit.
Wellness/alt-med edge. Heavy commercial pressure around "natural migraine cures" — magnesium, butterbur (now discouraged for hepatotoxicity), feverfew, essential oils, restrictive elimination diets. Effect sizes are modest at best; the danger is delay of evidence-based care.

Population variability

Sex. Childhood prevalence is roughly equal; the 3:1 female:male ratio opens at menarche and partially closes by late post-menopause.
Aura subgroup. ~25-30% of women with migraine have aura with at least some attacks. This subgroup carries the elevated stroke baseline and the combined-hormonal-contraceptive contraindication.
Menstrual subtype. Pure menstrual migraine ~7-10%, menstrually-related migraine ~50%, non-menstrual ~40%. Pure-menstrual responds well to perimenstrual mini-prevention; menstrually-related needs ongoing prevention.
Pregnancy course. ~80% improve, ~15% unchanged, ~5% worsen; migraine with aura is less likely to remit. Postpartum recurrence within one month is the rule.
Perimenopausal trajectory. Natural menopause: ~two-thirds improve, ~one-third unchanged or worse. Surgical menopause: large majority worse, often dramatically. Iatrogenic (chemotherapy-induced) menopause: similar to surgical.
Comorbidity. Depression (~25%), anxiety (~30%), patent foramen ovale (~40% in aura subgroup vs ~25% general), Raynaud phenomenon, irritable bowel, fibromyalgia, restless legs.
Demographics. AMPP data show higher prevalence in lower-income strata; this likely reflects both stress/sleep environmental exposure and lower access to specialist care. Race-stratified data are sparser; available U.S. evidence shows similar prevalence with worse care access for Black and Hispanic women.

Knowledge gaps

Long-term (5-10 year) real-world safety of CGRP-pathway blockade. The pathway has cardiovascular and gastrointestinal roles; population-scale post-marketing data are accumulating but rare adverse signals are not fully characterized.
Pregnancy and lactation safety for CGRP mAbs and gepants. Currently a 5-month washout before conception is advised conservatively; mechanistic concern (long IgG half-life, placental transfer, fetal CGRP roles) keeps trials off the table.
Whether modern prevention alters long-term cardiovascular/stroke trajectory in migraine-with-aura beyond symptomatic frequency reduction.
Mechanistic dissection of perimenopausal worsening — what fraction is estrogen-oscillation vs sleep disruption vs vasomotor instability vs mood comorbidity, and which is the most tractable intervention point.
Head-to-head data among CGRP mAbs and between CGRP agents and legacy preventives are sparse — most trials are vs placebo, leaving choice among agents driven by route, dosing interval, and access rather than comparative efficacy.
The role of progestin-only contraceptives in attack modulation — generally safe from a stroke-risk standpoint but their effect on attack frequency in menstrual migraine is mixed and under-studied.
Genetic and biomarker-based prediction of CGRP-mAb response; ~45-50% respond, ~50-55% don't, and there is no current way to predict in advance.

Brief coverage check. The description named four consequences — hormonal patterns and episode frequency, contraceptive choice and stroke risk in aura, perimenopausal trajectory, modern preventives. All four are covered end-to-end. No silent narrowing.

Structural decisions.

Placed contraindications before stakes, against the recommended early-mid placement for stakes. The aura-plus-combined-pill rule is the single highest-urgency clinical call in the entry — a scan-only reader needs to hit it before the felt-experience arc opens up. Stakes still sits before protocol per spec.
Ten addressing sections — more than the typical 3-6. The substance spans diagnosis, mechanism, contraceptive risk, pregnancy, perimenopause, and modern preventive therapy; each warranted real prose. Compressed practicalities (cost, access, prior auth) into the failure-modes section rather than giving it its own slot.
Used age-scoped audience sub-blocks inside the audience section to handle the three life-stage subgroups. Gender scoping is at the meta level (female), so the in-article blocks key on ages only.

Rating difficulties.

cost_burden at 3 reflects a U.S. private-insurance frame. Single-payer settings (UK NHS, Australian PBS, Canadian provincial formularies) typically subsidize CGRP-pathway drugs after meeting criteria, dropping the real-world burden lower. Kept the U.S. number because it's the more conservative call and the underlying medications are genuinely expensive at list price.
longevity at 2 is honest about a high-stakes, low-base-rate event (ischemic stroke in young women on combined hormonal contraception with aura). The relative risk is large (6-9x); the absolute event rate is modest in the population; the longevity dimension reads "small additive effect" at scale even though for the individual woman who avoided the stroke it was transformative.
Action type landed on decide rather than know. Migraine is partly a literacy problem (recognize aura) but the entry's load-bearing reader action is a sequence of decisions with clinician input — contraceptive method, when to escalate to prevention, HRT regimen, pregnancy planning.
Cadence as-needed rather than daily. Day-to-day prevention is daily once initiated, but the entry's frame is decision-events at life-stage transitions; daily compliance is a downstream consequence of those decisions.

Excluded by design.

Aura phenomenology beyond what's needed for the contraceptive rule — the full taxonomy of aura subtypes (basilar, hemiplegic, retinal, brainstem) is its own entry's worth.
Detailed pediatric migraine, the male-predominant trigeminal autonomic cephalalgias, and post-traumatic headache. Pointed to in out-of-scope.
Deep dose-titration tables and side-effect profiles for each preventive agent — protocol-level detail beyond "what to ask for" was kept compressed; expanded versions belong with the prescribing clinician.

Separate-entry candidates.

Hormone replacement therapy in women — adjacent to the perimenopause material; large enough topic to deserve its own entry rather than absorbed here.
Medication-overuse headache — flagged in failure-modes, but the topic of how to detox from it deserves its own treatment.
Idiopathic intracranial hypertension — female-predominant headache with visual changes that can mimic aura. Distinct mechanism (weight and CSF pressure), distinct workup, would mis-fit here.
CGRP-pathway preventives as a substance-level entry — could double as cross-link target once written, since multiple women's-health entries will refer to them.

Future links. When entries exist, cross-link from this one to: HRT in women; medication-overuse headache; idiopathic intracranial hypertension; sleep regularity (the trigger story); aerobic exercise (preventive evidence).

Sources held back. The dossier cites Brandes2006 (JAMA review on estrogen and migraine), MacGregor2015 (Continuum review on menstrual and menopausal management), and Croop2021 (Lancet rimegepant preventive trial) without re-using them in the article body — dossier-as-superset.